ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Price & Overview
NASDAQ:ADPT • US00650F1093
Current stock price
The current stock price of ADPT is 14.81 USD. Today ADPT is up by 2.63%. In the past month the price decreased by -7.03%. In the past year, price increased by 98.26%.
ADPT Key Statistics
- Market Cap
- 2.28B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.40
- Dividend Yield
- N/A
ADPT Stock Performance
ADPT Stock Chart
ADPT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT is one of the better performing stocks in the market, outperforming 88.19% of all stocks.
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADPT. ADPT may be in some trouble as it scores bad on both profitability and health.
ADPT Earnings
On February 5, 2026 ADPT reported an EPS of -0.09 and a revenue of 71.68M. The company beat EPS expectations (51.32% surprise) and beat revenue expectations (18.33% surprise).
ADPT Forecast & Estimates
14 analysts have analysed ADPT and the average price target is 21.27 USD. This implies a price increase of 43.65% is expected in the next year compared to the current price of 14.81.
For the next year, analysts expect an EPS growth of -23.67% and a revenue growth 6.68% for ADPT
ADPT Groups
Sector & Classification
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 63.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.6% | ||
| ROE | -27.19% | ||
| Debt/Equity | 0.58 |
ADPT Ownership
ADPT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.82 | 183.712B | ||
| DHR | DANAHER CORP | 22.51 | 134.915B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 134.21 | 43.766B | ||
| A | AGILENT TECHNOLOGIES INC | 17.26 | 32.369B | ||
| WAT | WATERS CORP | 20.94 | 29.419B | ||
| IQV | IQVIA HOLDINGS INC | 13.52 | 28.941B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.86 | 25.901B | ||
| ILMN | ILLUMINA INC | 24.35 | 19.362B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.45 | 18.218B | ||
| MEDP | MEDPACE HOLDINGS INC | 28.59 | 13.891B | ||
| RVTY | REVVITY INC | 16.13 | 9.829B | ||
| CRL | CHARLES RIVER LABORATORIES | 15.59 | 8.61B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 8.408B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
IPO: 2019-06-27
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 624
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you describe the business of ADAPTIVE BIOTECHNOLOGIES?
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
What is the current price of ADPT stock?
The current stock price of ADPT is 14.81 USD. The price increased by 2.63% in the last trading session.
Does ADAPTIVE BIOTECHNOLOGIES pay dividends?
ADPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADPT stock?
ADPT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for ADPT stock?
14 analysts have analysed ADPT and the average price target is 21.27 USD. This implies a price increase of 43.65% is expected in the next year compared to the current price of 14.81.
How is the valuation of ADAPTIVE BIOTECHNOLOGIES (ADPT) based on its PE ratio?
ADAPTIVE BIOTECHNOLOGIES (ADPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
Would investing in ADAPTIVE BIOTECHNOLOGIES be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADPT.